We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Les cancers biliaires à l'ère des thérapies ciblées.
- Authors
Colle, Raphael; Malka, David
- Abstract
The AFEF and ESMO 2022 symposia have outlined one of the three recent developments in the management of biliary tract cancers, along with the definition of standard chemotherapies and the entry of immune checkpoint inhibitors into the therapeutic arsenal, namely, the contribution of precision medicine. Biliary tract cancers, and particularly intrahepatic cholangiocarcinomas, are rich in targetable molecular alterations. This fact imposes a more marked attention to the quantity and quality of tumor samples and a multidisciplinary work with samplers, pathologists and molecular biologists in order to advance jointly and as soon as possible in the diagnosis and the molecular characterization of these cancers. Among the targets of interest, IDH1 mutations and FGFR2 fusions are the more frequent ones, for which inhibitors are already available.
- Subjects
BILIARY tract cancer; IMMUNE checkpoint inhibitors; MOLECULAR biologists; INDIVIDUALIZED medicine; MOLECULAR diagnosis; GALLBLADDER cancer
- Publication
Hépato-Gastro & Oncologie Digestive, 2023, Vol 30, p4
- ISSN
2115-3310
- Publication type
Proceeding
- DOI
10.1684/hpg.2023.2556